Regeneron Pharmaceuticals (REGN) Other Non-Current Assets (2009 - 2026)

Regeneron Pharmaceuticals' Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 52.87% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 52.87% YoY), while the FY2025 annual figure was $1.8 billion, up 60.32% from the prior year.
• Other Non-Current Assets was $2.1 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $1.8 billion in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.1 billion in Q1 2026 to a low of $262.0 million in Q1 2022.
• Historically, Other Non-Current Assets has averaged $881.3 million across 5 years, with a median of $470.2 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets rose 28.01% in 2023, then jumped 196.28% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $336.4 million in 2022, then soared by 32.02% to $444.1 million in 2023, then soared by 155.8% to $1.1 billion in 2024, then surged by 60.32% to $1.8 billion in 2025, then rose by 16.94% to $2.1 billion in 2026.
• The last three Other Non-Current Assets figures came in at $2.1 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.